By Cort Johnson in Health Rising.
Ivabradine appears to work quite well in POTS – but should we stop there?
Ivabradine was approved for use in the European Union in 2005, but it’s pretty new to the scene in the U.S. It was FDA approved in only 2015. That means it doesn’t have much of a history but it would be accurate to say that it hit the (postural orthostatic tachycardia syndrome) POTS community in the U.S. with a bang.
(Check out Ivabradine on Wikipedia or Corlanor on Drugs.com, though, and you won’t even get a hint that it might useful for POTS. Corlanor, for them, is a heart failure drug that inhibits a “pacemaker current”, thereby reducing pacemaker activity and slowing heart rate – allowing the heart to fill with more blood.)
Ivabradine goes by the trade name Corlanor in the U.S., Procoralan (worldwide), Coralan (in Hong Kong, Singapore, Australia and some other countries), Corlentor (in Armenia, Spain, Italy and Romania), Lancora (in Canada) and Coraxan (in Russia and Serbia), Ivabrad, Ivabid, IVAMAC and Bradia (in India).
To read the rest of this story, click on the link below: